Summary
The platelet is one of the most researched biological markers in psychiatry. Characteristics of MAO activity, 5-HT uptake, imipramine andα 2-adrenergic receptor binding, for example, are similar in platelet and CNS. Methodological factors are not negligible, and range from diagnostic specificity and drug effects to the normal physiological variability of age and hormone-related changes, circadian and seasonal rhythms. As yet, there are no clear state or trait platelet markers in affective disorders and schizophrenia that can be unequivocally used to detect vulnerability to the illness, predict therapeutic response, define clinical diagnostic entities or follow the course of the illness. However, platelet markers are increasingly being used in careful studies to monitor psychopharmacological effects (an in vivo assay of all active metabolites), different ligands can be specific markers for certain aspects of a psychiatric illness (e.g.α 2-adrenergic receptors and weight loss), and this homogeneous preparation of human cells is an increasingly important tool in studying mechanisms in pathophysiology. More longitudinal studies are required to establish functional relationships between platelet variables and psychopathology.
Similar content being viewed by others
References
Ackenheil, M., Bondy, B., and Fröhler, M., Interactions between catecholamines and their receptors in blood. Clin. Neuropharmac.9 (1986) 119–121.
Ahtee, L., Briley, M., Raisman, R., Lebree, D., and Langer, S. Z., Reduced uptake of serotonin but unchanged3H-imipramine binding in the platelets from cirrhotic patients. Life Sci.29 (1981) 2323–2329.
Albus, M., Bondy, B., and Ackenheil, M., Adrenergic receptors on blood cells: Relation to the pathophysiology of anxiety. Clin. Neuropharmac.9 (1986) 359–361.
American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC 1980.
Arora, R. C., and Meltzer, H. Y., Serotonin uptake by blood platelets of schizophrenic patients. Psychiat. Res.6 (1982) 327–333.
Arora, R. C., Kregel, L., and Meltzer, H. Y., Circadian rhythm of serotonin uptake in the blood platelets of normal controls. Biol. Psychiat.19 (1984) 1579–1584.
Arora, R. C., Kregel, L., and Meltzer, H. Y., Seasonal variation of serotonin uptake in normal controls and depressed patients. Biol. Psychiat.19 (1984) 795–804.
Arora, R. C., Wunnicke, V., and Meltzer, H. Y., Effect of protein concentration on kinetic constants of3H-imipramine binding in blood platelets. Biol. Psychiat.20 (1985) 94–119.
Asarch, K. B., Shrih, J. C., and Kulcrar, A., Decreased3H-imipramine binding in depressed males and females. Commun. Psychopharmac.4 (1980) 425–432.
Asberg, M., Biochemical aspects of suicide. Clin. Neuropharm.9 (1986) 374–376.
Barkai, A. I., Kowalik, S., and Baron, M., Effect of membrane protein concentration on binding of3H-imipramine in human platelets. Biol. Psychiat.20 (1985) 199–228.
Baron, M., Barkai, A., and Gruen, R., Platelet [3H]-imipramine binding in affective disorders: trait versus state characteristics. Am. J. Psychiat.143 (1986) 711.
Berrettini, W. H., Nurnberger, J. I., Worthington, E. K., Simmons-Alling, S., and Gershon, E. S., Platelet vasopressin receptors in bipolar affective illness. Psychiat. Res.7 (1982) 83–86.
Braddock, L. E., Cowen, P. J., Elliot, J. M., Fraser, S., and Stump, K., Changes in platelet3H-imipramine and3H-yohimbine binding in normal subjects taking amitriptyline. Neuropharm.23 (1984) 285–286.
Briley, M., Imipramine binding: its relationship with serotonin uptake and depression, in: Neuropharmacology of Serotonin, pp. 50–78. Ed. A. R. Green, Oxford University Press, Oxford 1985.
Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D., and Zarifian, E., Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science209 (1980) 303–305.
Brodde, O. E., Anlauf, M., Graben, N., and Bock, K. D., Age-dependant decrease ofα2-adrenergic receptor number in human platelets. Eur. J. Pharmac.81 (1982) 345–347.
Buchsbaum, M. S., Coursey, R. D., and Murphy, D. L., The biochemical high-risk paradigm: Behavioral and familial correlates of low platelet monoamine oxidase activity. Science194 (1976) 339–341.
Buckley, C., Curtin, D., Walsh, T., and O’Malley, K., Ageing and plateletα2-adrenoceptors. Br. J. clin. Pharmac.21 (1986) 721–722.
Cameron, O. G., Smith, C. B., Hollingsworth, P. J., Nesse, R. M., and Curtis, G. C., Plateletα2-adrenoceptors receptor binding and plasma catecholamines. Archs gen. Psychiat.14 (1984) 1144–1148.
Campell, I. C., Blood platelets and psychiatry. Br. J. Psychiat.138 (1981) 78–80.
Carstens, M. E., Engelbrecht, A. H., Russell, V. A., Aalbers, C., Gagiano, C. A., Chalton, D. O., and Taljaard, J. J. F., Imipramine binding sites on platelets of patients with major depressive disorder. Psychiat. Res.18 (1986) 333–342.
Carstens, M. E., Engelbrecht, A. H., Russell, V. A., Aalbers, C., Gagiano, C. A., Chalton, D. O., and Taljaard, J. J. F., Alpha-2-adrenoceptor levels on platelets of patients with major depressive disorders. Psychiat. Res.18 (1986) 321–331.
Cloninger, C. R., von Knorring, L., and Oreland, L., Pentametric distribution of platelet monoamine oxidase activity. Psychiat. Res.15 (1985) 133–143.
Coppen, A., Swade, C., and Wood, K., Platelet 5-hydroxytryptamine accumulation in depressive illness. Clinica chim. Acta87 (1978) 165–168.
Corash, L., Platelet heterogeneity: relevance to the use of platelets to study psychiatric disorders. Schizophrenia Bull.6 (1980) 255–258.
Daiguji, M., Meltzer, H. Y., Tong, C., U’Prichard, D. C., Young, M., and Kravitz, H., Alpha-2-adrenergic receptors in platelet membranes of depressed patients: No change in number or3H-yohimbine affinity. Life Sci.29 (1981) 2059–2064.
Doyle, M. C., George, A. J., Ravindran, A. V., and Philpott, R., Plateletα2-adrenoceptors binding in elderly depressed patients. Am. J. Psychiat.142 (1985) 1489–1490.
Ebstein, R. P., Lerer, B., Bennett, E. R., Ben Dayek, D., Newman, M. E., Shapira, B., and Kindler, S., Second messenger function in lymphocytes and platelets: A comparison of peripheral and central mechanisms. Clin. Neuropharmac.4 (1986) 350–352.
Egrise, D., Desmedt, D., Schoutens, A., and Mendlewicz, J., Circannual variations in the density of tritiated imipramine binding sites on blood platelets in man. Neuropsychobiology10 (1983) 101–102.
Egrise, D., Rubinstein, M., Schoutens, A., Cantraine, F., and Mendlewicz, J., Seasonal variation of platelet serotonin uptake and3H-imipramine binding in normal and depressed subjects. Biol. Psychiat.21 (1986) 283–292.
Ehsanullah, R. S. B., Uptake of 5-hydroxytryptamine and dopamine into platelets from depressed patients and normal subjects-influence of clomipramine, desmethylclomipramine and maprotiline. Postgrad. med. J., Suppl. 1 (1980) 31–35.
Elliott, J. M., Platelet receptor binding studies in affective disorders. J. affect. Dis.6 (1984) 219–239.
Friedl, W., Propping, P., and Weck, B.,3H-Imipramine binding in platelets: influence of varying proportions of intact platelets in membrane preparations on binding. Psychopharmacology80 (1983) 96–99.
Fröhler, M., Saito, Y., Ackenheil, M., Bak, R., Bondy, B., Feistenauer, E., Hofschuster, E., Vakis, A., and Welter, D., Catecholaminergic binding sites on blood cells of healthy volunteers with special respect to circadian rhythms. Pharmacopsychiatry1 (1985) 147–148.
Galzin, A. M., Loo, H., Sechter, D., and Langer, S. Z., Lack of seasonal variation in platelet [3H]-imipramine binding in humans. Biol. Psychiat.21 (1986) 876–882.
Garcia-Sevilla, J. A., Zis, A. P., Hollingsworth, P. J., Greden, J. F., and Smith, C. B., Plateletα2-adrenergic receptors in major depressive disorder. Archs. gen. Psychiat.38 (1981) 1327–1333.
Garcia-Sevilla, J. A., Zis, A. P., Zelnik, T. C., and Smith, C. B., Tricyclic antidepressant drug treatment decreases alpha-2-adrenoceptors on human platelet membranes. Eur. J. Pharmac.69 (1981) 121–122.
Gay, C., Langer, S. Z., Loo, H., Raisman, R., Sechter, D., and Zarifian, E.,3H-Imipramine binding in platelets-a state-dependent biological marker in depression? Br. J. Pharmac. Chemother.78 (1983) 57P.
Gentsch, C., Lichtsteiner, M., Gastpar, M., Gastpar, G., and Feer, H.,3H-Imipramine binding sites in platelets of hospitalized psychiatric patients. Psychiat. Res.14 (1984) 177–187.
Hallstrom, C. O. S., Pare, C. M. B., Rees, W. L., Trenchard, A., and Turner, P., Platelet uptake of 5-hydroxytryptamine and dopamine in depression. Postgrad. med. J.52 (1976) 40–44.
Hamilton, C. A., Jones, C. R., Mishra, N., Barr, S., and Reid, J. L., A comparison ofα2-adrenoceptors regulation in brain and platelets. Brain Res.347 (1985) 350–353.
Haug, H. J., Fähndrich, E., Strauss, S., and Rommelspacher, H., Sleep deprivation and imipramine binding sites in depressed patients and healthy subjects. Psychiat. Res. (1987) in press.
Heufelder, A., Warnhoff, M., and Pirke, K. M., Plateletα2-adrenoceptors and adenylate cyclase in patients with anorexia nervosa and bulimia. J. clin. Endocr. Metab.61 (1985) 1053–1060.
Hrdina, P. D., Lapierre, Y. D., Horn, E. R., and Bakish, D., Platelet3H-imipramine binding: A possible predictor of response to antidepressant treatment. Prog. Neuropsychopharmac. Biol. Psych.9 (1985) 619–622.
Humphries, L. L., Shirley, P., Allen, M., Codd, E. E., and Walker, R. F., Daily patterns of serotonin uptake in platelets from psychiatric patients and control volunteers. Biol. Psychiat.20 (1985) 1073–1081.
Jackman, H. Y., and Meltzer, H. Y., Factors affecting determination of platelet monoamine oxidase activity. Schizophrenia Bull.6 (1980) 259–262.
Jones, S. B., Bylund, D. B., Rieser, C. A., Shekim, W. O., and Byer, J. A.,α2-Adrenergic receptor binding in human platelets: Alterations during the menstrual cycle. Clin. Pharmac. Ther.34 (1983) 90–96.
Kafka, M. S. and Paul, S. M., Plateletα2-adrenergic receptors in depression. Archs gen. Psychiat.43 (1986) 91–95.
Kafka, M. S., Siever, L. J., Nurnberger, J. I., Uhde, T. W., Targum, S., Cooper, D. M. J., Kammen, D. P., and Tokola, N. S., Platelet alpha-adrenergic receptor function in affective disorders and schizophrenia. Psychopharmac. Bull.21 (1985) 599–602.
Kaye, W. H., Gwirtsman, H. E., Lake, R., Siever, L. J., Jimerson, D. C., Ebert, M. H., and Murphy, D. L., Disturbances of norepinephrine metabolism andα2-adrenergic receptor activity in anorexia nervosa: Relationship to nutritional state. Psychopharmac. Bull.21 (1985) 419–423.
von Knorring, L., Oreland, L., and Winblad, B., Personality traits related to monoamine oxidase activity in platelets. Psychiat. Res.12 (1984) 11–26.
Ko, G. N., Unnerstall, J. R., Kuhar, M. J., Wyatt, R. J., and Kleinman, J. E., Alpha-2-adrenergic agonist binding in schizophrenic brains. Psychopharmac. Bull.22 (1986) 1011–1016.
Langer, S. Z., Zarifian, E., Briley, M., Raisman, R., and Sechter, D., High-affinity binding of3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci.29 (1981) 211–220.
Langer, S. Z., Zarifian, E., Briley, M., Raisman, R., and Sechter, D., High affinity3H-imipramine binding: A new biological marker in depression. Pharmacopsychiatry15 (1982) 4–10.
Lewis, D. A., and McChesney, C., Tritiated imipramine binding to platelets in manic subjects. J. affect. Dis.9 (1985) 207–211.
Lewis, D. A., Noyes, R., Coryell, W., and Clancy, J., Tritiated imipramine binding to platelets is decreased in patients with agoraphobia. Psychiat. Res.16 (1985) 1–9.
Lingjaerde, O., Blood platelets as a model system for studying the biochemistry of depression, in: Frontiers in Biochemical and Pharmacological Research in Depression, pp. 99–111. Ed. F. Sjöquist. Raven Press, New York 1984.
Lingjaerde, O., Serotonin uptake and efflux in blood platelets from untreated and neuroleptic-treated schizophrenics. Biol. Psychiat.18 (1983) 1345–1356.
Luck, P., Mikhailidis, D. P., Dashwood, M. R., Barradas, M. A., Sever, P. S., Dandona, P., and Wakeling, A., Platelet hyperaggregability and increased α-adrenoceptor density in anorexic nervosa. J. clin. Endocr. Metab.57 (1983) 911–914.
Malmgren, R., Asberg, M., Olsson, P., Tornling, G., and Unge, G., Defective serotonin transport mechanism in platelets from endogenously depressed patients. Life Sci.29 (1981) 2649–2658.
Mellerup, E. T., Plenge, P., and Rosenberg, R.,3H-Imipramine binding sites in platelets from psychiatric patients. Psychiat. Res.7 (1982) 221–227.
Meltzer, H. Y., Arora, R. C., and Goodnick, P., Effect of lithium carbonate on serotonin uptake in blood platelets of patients with affective disorders. J. affect. Dis.5 (1983) 215–221.
Meltzer, H. Y., Arora, R. C., Tricou, B. J., and Fang, V. S., Serotonin uptake in blood platelets and the dexamethasone suppression test in depressed patients. Psychiat. Res.8 (1983) 41–47.
Meyerson, L. R., Wennogle, L. P., Abel, M. S., Coupet, J., Lippa, A. S., Rauh, C. E., and Beer, B., Human brain receptor alterations in suicide victims. Pharmac. biochem. Behav.17 (1982) 159.
Modai, I., Zemishlany, Z., and Jerushalmy, Z., 5-Hydroxytryptamine uptake by blood platelets of unipolar and bipolar depressed patients. Neuropsychobiology12 (1984) 93–95.
Modai, I., Malmgren, R., Asberg, M., and Beving, H., Circadian rhythm of serotonin transport in human platelets. Psychopharmacology88 (1986) 493–495.
Modai, I., Rotman, A., Munitz, H., Tjano, S., and Wijsenbeek, H., Serotonin uptake by blood platelets of acute schizophrenic patients. Psychopharmacology64 (1979) 193–195.
Mück-Seler, D., Deanovic, Z., Jamnicky, B., Jakupcevic, M., and Mihovilovic, M., Maprotiline in the treatment of endogenous depression: Comparison of therapeutic effect with serotonin level in blood platelets. Psychopharmacology79 (1983) 262–265.
Murphy, D. L., Lipper, S., Pickar, D., Jimerson, D., Cohen, R. M., Garrick, N. A., Alterman, I. S., and Campbell, I. C., Selective inhibition of monoamine oxidase type A: Clinical antidepressant effect and metabolic changes in man, in: Monoamine Oxidase Inhibitors. The State of the Art, pp. 189–205. Eds M. B. Youdim and E. S. Paykel. John Wiley, Chichester 1981.
Murphy, D. L., Wright, C., Buchsbaum, M. S., Nichols, A., Costa, J. L., and Wyatt, R. J., Platelet and plasma amine oxidase activity in 680 normals: Sex and age diferences and stability over time. Biochem. Med.16 (1976) 254–265.
Muscettola, G., DiLauro, A., and Giannini, C. P., Platelet3H-imipramine binding in bipolar patients. Psychiat. Res.18 (1986) 343–353.
Muscettola, G., DiLauro, A., and Giannini, C. P., Blood cells as biological trait markers in affective disorders. J. psychiat. Res.18 (1984) 447–456.
Nankai, M., Yoshimoto, S., Narita, K., and Takahashi, R., Platelet [3H] imipramine binding in depressed patients and its circadian variations in healthy controls. J. affect. Dis.11 (1986) 207–212.
Nies, A., Robinson, D. S., Lamborn, K. R., Lampert, R. T., and Burlington, V. T., Genetic control of platelet and plasma monoamine oxidase activity. Archs gen. Psychiat.28 (1973) 834–838.
Norman, T. R., Judd, F. K., Gregory, M., James, R. H., Kimber, N. M., McIntyre, D. M., and Burrows, G. D., Platelet serotonin uptake in panic disorder. J. affect. Dis.11 (1986) 69–72.
Oreland, L., Wiberg, A., and Fowler, C. J., Monoamine oxidase activity in platelets as related to monoamine oxidase activity and monoaminergic function in the brain. Adv. Neuropsychopharmac.9 (1981) 195–201.
Paul, S. M., Rehavi, M., Skolnick, P., Ballenger, J. C., and Goodwin, F. K., Depressed patients have decreased binding of3H-imipramine to the platelet serotonin ‘transporter’. Archs gen. Psychiat.38 (1981) 1315–1317.
Pecknold, J. C., and Suranyi-Cadotte, B. E., Panic disorder and depression: 5 HT and imipramine binding studies. Clin. Neuropharmac.9 (1986) 46–48.
Perry, E. K., Marshall, E. F., Blessed, G., Tomlinson, B. E., and Perry, R. H., Decreased imipramine binding in the brains of patients with depressive illness. Br. J. Psychiat.142 (1983) 188–192.
Piletz, J. E., and Halaris, A., Yohimbine and clonidine recognize different states of adrenergic receptors on human platelets: Reconsideration of studies on platelet alpha-2-receptors in depressive illness. Psychopharmac. Bull.21 (1985) 573–578.
Pletscher, A., Affolter, H., Cesura, M., Erne, E., and Müller, K., Blood platelets as models for neurons: Similarities of the 5-hydroxytryptamine systems, in: Progress in Tryptophan and Serotonin Research, pp. 231–239. Eds H. G. Schlossberger, W. Kochen, B. Linzen, and H. Steinhart. de Gruyter W. & Co., Berlin 1984.
Poirier, M. F., Benkelfat, Ch., Galzin, A. M., and Langer, S. Z., Platelet3H-imipramine binding and steroid hormone serum concentrations during the menstrual cycle. Psychopharmacology88 (1986) 86–89.
Raisman, R., Sechter, D., Briley, M. S., Zarifian, E., and Langer, S. Z., High affinity3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers. Psychopharmacology75 (1982) 268–371.
Rausch, J. L., Shah, N. S., Burch, E. A., Donald, A. G., and Munson, E. V., A study of circadian variation of platelet serotonin uptake and serum cortisol in patients with major depression, in: Psychoneuroendocrinology in Psychiatry and Neurology, pp. 473–485. Ed. N. S. Shah. Plenum Press, New York 1984.
Rausch, J. L., Shah, N. S., Burch, E. A., and Donald, A. G., Platelet serotonin uptake in depressed patients: Circadian effect. Biol. Psychiat.17 (1982) 121–123.
Rehavi, M., Paul, S., Skolnick, P., and Goodwin, F. K., Demonstration of specific high affinity binding sites for3H-imipramine in human brain. Life Sci.16 (1980) 2273–2279.
Rice, J., McGuffin, P., Goldin, L. R., Shaskan, E. G., and Gershon, E. S., Platelet monoamine oxidase (MAO) activity: Evidence for a single major locus. Am. J. hum. Genet.36 (1984) 36.
Rieder, R., and Gershon, E. S., Genetic strategies in biological psychiatry. Archs gen. Psychiat.35 (1978) 866–873.
Robinson, D. S., and Nies, A., Demographic and other variables affecting monoamine oxidase activity. Schizophrenia Bull.2 (1980) 298–307.
Rose, S. P. R., and Murphy, S., Psychotherapy and imipramine binding to blood platelets. Abstract IBRO Conference, Budapest 1987.
Rosen, J., Silk, K. R., Rice, H. E., and Smith, C. B., Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: A preliminary study. Biol. Psychiat.20 (1985) 539–545.
Rotman, A., Blood platelets in psychopharmacological research. Progr. Neuropsychopharmac.6 (1982) 57–61.
Rotman, A., Zemishlany, Z., Munitz, H., and Wijsenbeek, H., The active uptake of serotonin by platelets of schizophrenic patients and their families: possibility of a genetic marker. Psychopharmacology77 (1982) 171–174.
Sarai, K., and Kayano, M., The level and diurnal rhythm of serotonin in manic-depressive patients. Folia psychiat. neurol. jap.22 (1968) 271–280.
Schneider, L. S., Munjack, D., Severson, J. A., and Palmer, R., Platelet [3H] imipramine binding in generalized anxiety disorders, panic disorder, and agoraphobia with panic attacks. Biol. Psychiat.22 (1987) 59–66.
Scott, M., Reading, H. W., and Loudon, J. B., Studies on human blood platelets in affective disorder. Psychopharmacology60 (1979) 131–135.
Siever, L. J., Kafka, M. S., Targum, S., and Lake, C. R., Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls. Psychiat. Res.11 (1984) 287–302.
Siever, L. J., Kafka, M. S., Insel, T. R., Lake, C. R., and Murphy, D. L., Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses. Psychiat. Res.9 (1983) 37–44.
Smith, C. B., Hollingsworth, P. J., Garcia-Sevilla, J. A., and Zis, A. P., Platelet alpha-2-adrenoreceptors are decreased in number after antidepressant therapy. Prog. Neuropsychopharmac.7 (1983) 241–247.
Stahl, S. M., Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons, in: The Platelet: Physiology and Pharmacology, pp. 307–340. Academic Press, New York 1985.
Stahl, S. M., Peripheral models for the study of neurotransmitter receptors in man. Psychopharmac. Bull.21 (1985) 663–671.
Stahl, S. M., Lemoine, P. M., Ciaranello, R. D., and Berger, P. A., Platelet alpha-2-adrenergic receptor sensitivity in major depressive disorder. Psychiat. Res.10 (1983) 157–164.
Stahl, S. M., Woo, D. J., Mefford, I. N., Berger, P. A., and Ciaranello, R. D., Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am. J. Psychiat.140 (1983) 26–30.
Stanley, M., Virgilio, J., and Gershon, S., Tritiated imipramine bindings sites are decreased in the frontal cortex of suicides. Science216 (1982) 1337–1339.
Sundaresan, P. R., Madan, M. K., Kelvie, S. L., and Weintraub, M., Platelet alpha-2-adrenoceptors and the menstrual cycle. Clin. Pharmac. Ther.37 (1985) 337–342.
Sundaresan, P. R., Weintraub, M., Hershey, L. A., Kroening, B. H., Hasday, J. D., and Banerjee, S. P., Platelet alpha-2-adrenergic receptors in obesity: Alteration with weight loss. Clin. Pharmac. Ther.33 (1983) 776–785.
Suranyi-Cadotte, B., Wood, P. L., Schwartz, G., and Nair, N. P. V., Altered platelet3H-imipramine binding in schizo-affective and depressive disorders. Biol. Psychiat.18 (1983) 923–927.
Suranyi-Cadotte, B. E., Gauthier, S., Lafaille, F., DeFlores, S., Dam, T. V., Nair, N. P. V., and Quirion, R., Platelet3H-imipramine binding distinguishes depression from Alzheimer dementia. Life Sci.37 (1985) 2305–2323.
Suranyi-Cadotte, B. E., Wood, P. L., Nair, N. P. V., and Schwartz, G., Normalisation of platelet3H-imipramine binding in depressed patients during remission. Eur. J. Pharmac.85 (1982) 357–358.
Swade, C., and Coppen, A., Seasonal variations in biochemical factors related to depressive illness. J. affect. Dis.2 (1980) 249–255.
Tam, W. Y. K., Chan Mo-Yin, and Lee, P. H. K., The menstrual cycle and platelet 5-HT uptake. Psychosom. Med.47 (1985) 352–362.
Tang, S. W., and Morris, J. M., Variation in human platelet3H-imipramine binding. Psychiat. Res.16 (1985) 141–146.
Tanimoto, K., Maeda, K., and Terada, T., Alteration of platelet [3H] imipramine binding in mildly depressed patients correlates with disease severity. Biol. Psychiat.20 (1985) 329–352.
Tuomisto, J., and Tukiainen, E., Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature262 (1976) 596–598.
Uhde, T. W., Berrettini, W. H., Roy-Byrne, P. P., Ballenger, J. P., and Post, R. M., Platelet [3H] imipramine binding in patients with panic disorder. Biol. Psychiat.22 (1987) 52–58.
Wägner, A., Aberg-Wistedt, A., Asberg, M., Ekqvist, B., Märtensson, B., and Montero, D., Lower3H-imipramine binding in platelets from untreated depressed patients compared to healthy controls. Psychiat. Res.16 (1985) 131–139.
Weizman, R., Carmi, M., Tyano, S., Apter, A., and Rehavi, M., High affinity [3H] imipramine binding and serotonin uptake by platelets of adolescent females suffering from anorexia nervosa. Life Sci.38 (1986) 1235–1242.
Whitaker, P. M., Warsh, J. J., Stancer, H. C., Persad, E., and Vint, C. K., Seasonal variation in platelet3H-imipramine binding: Comparable values in control and depressed populations. Psychiat. Res.11 (1984) 127–141.
Winblad, B., Gottfries, C. G., Oreland, L., and Wiberg, A., Monoamine oxidase in platelets and brain of non-psychiatric and non-neurological geriatric patients. Med. Biol.57 (1981) 129–132.
Wirz-Justice, A., and Chappuis-Arndt, E., Sex specific differences in chlorimipramine inhibition of serotonin uptake in human platelets. Eur. J. Pharmac.40 (1976) 21–25.
Wirz-Justice, A., and Pühringer, W., Chronic treatment with clomipramine or maprotiline depletes platelet serotonin and modifies its diurnal rhythm. Prog. Neuropsychopharmac.2 (1978) 217–224.
Wirz-Justice, A., and Pühringer, W., Increased platelet serotonin in bipolar depression and hypomania. J. neural Transm.42 (1978) 55–62.
Wirz-Justice, A., and Pühringer, W., Seasonal incidence of an altered diurnal rhythm of platelet serotonin in unipolar depression. J. neural Transm.42 (1978) 45–53.
Wirz-Justice, A., and Richter, R., Seasonality in biochemical determinations: A source of variance and a clue to the temporal incidence of affective illness. Psychiat. Res.1 (1979) 53–60.
Wirz-Justice, A., Lichtsteiner, M., and Feer, M., Diurnal and seasonal variations in human platelet serotonin. J. neural Transm.41 (1977) 7–15.
Wirz-Justice, A., Pühringer, W., Hole, G., and Menzi, R., Monoamine oxidase and free tryptophan in human plasma: Normal variations and their implications for biochemical research in affective disorders. Pharmakopsychiat. Neuro-Psychopharmak.8 (1975) 309–317.
Wood, K., and Coppen, A., Prophylactic lithium treatment of patients with affective disorders is associated with decreased platelet [3H] dihydroergocryptine binding. J. affect. Dis.5 (1983) 253–258.
Wood, K., Swade, C., Abou-Saleh, M. T., and Coppen, A., Apparent supersensitivity of platelet 5-HT receptors in lithium-treated patients. J. affect. Dis.8 (1985) 69–72.
Wood, P. L., Suranyi-Cadotte, B., Nair, N. P. V., LaFaille, F., and Schwartz, G., Lack of association between [3H] imipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients. Neuropharmacology22 (1983) 1211–1214.
Wood, P. L., Suranyi-Cadotte, B., Schwartz, G., and Nair, N. P., Platelet3H-imipramine binding and red blood cell choline in affective disorders: indications of heterogeneous pathogenesis. Biol. Psychiat.18 (1983) 715–719.
Zubin, J., Psychobiological markers for schizophrenia: State of the art and future perspectives. Psychopharmac. Bull.21 (1985) 490–496.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wirz-Justice, A. Platelet research in psychiatry. Experientia 44, 145–152 (1988). https://doi.org/10.1007/BF01952199
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01952199